Entry into the European market is an important step for the company in its quest to become one of the world's leading pharmaceutical companies. “We looked at various possibilities, but Basel stood out as the location in which to build our European business,” says Michael Frizberg, general manager of Luye Supply AG, about the company's decision.
Proximity to other global pharmaceutical companies and access to a large pool of highly qualified talents were amongst our key requirements for the new European hub. BaselArea.swiss helped us to expand our network and provides a valuable platform for knowledge transfer with other innovative companies by organizing various events.
Flourishing ecosystem and international networking
With its own product pipeline focusing on active ingredient patches and with several subsidiaries abroad, Luye Pharma is a pioneer in the Chinese pharmaceutical industry. The company acquired the transdermal drug delivery systems business (TTS) from the Swiss company Acino in 2016, which complemented the Group’s development efforts in R&D, international licensing and distribution.
The Basel Region has a thriving life sciences ecosystem. It occupies a leading position when it comes to innovation and has the highest concentration of life sciences companies in Switzerland. The location also directly borders with France and Germany and offers convenient access to the European market with its airport. An international flair and high standards of living are further advantages that contributed to Basel’s selection.
About Luye Pharma
Luye Pharma is a leading Chinese pharmaceutical company driven by innovation. It primarily focuses on therapeutic areas such as the central nervous system, oncology, cardiovascular and metabolic diseases. Since its foundation, Luye Pharma has focused on innovation and globalization as key drivers of growth. Luye Pharma is one of the first Chinese companies to have carried out clinical trials on international markets. It currently has several innovative products with breakthrough results in various stages of clinical research in the US.